← Back to Clinical Trials
Recruiting NCT06340438

NCT06340438 Investigate the Relationship Between Catastrophizing and the Perception of Itch Intensity in Healthy Individuals

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06340438
Status Recruiting
Phase
Sponsor Aalborg University
Condition Histamine
Study Type INTERVENTIONAL
Enrollment 46 participants
Start Date 2024-04-27
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
HistamineCowhage

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 46 participants in total. It began in 2024-04-27 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project aims to investigate the relationship between different dimensions of catastrophizing (rumination, magnification, and helplessness) as well as some specific personality traits related to catastrophizing tendencies like anxiety sensitivity and fear sensitivity in the modulation of itch and pain intensities in an experimental setting.

Eligibility Criteria

Inclusion Criteria: * Healthy men and women * 18-60 years * Speak and understand English Exclusion Criteria: * Pregnancy or lactation * Drug addiction defined as any use of cannabis, opioids, or other addictive drugs * Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis), musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder, or mental illnesses that may affect the results * Lack of ability to cooperate * Current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids * Skin diseases (e.g. atopic dermatitis, pruritus nodularis, eczema, psoriasis) * Moles, scars, or tattoos in the area to be treated or tested. * Consumption of alcohol or painkillers 24 hours before the study days and between these * Acute or chronic pain * Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)

Contact & Investigator

Central Contact

Silvia Lo Vecchio, PhD

✉ slv@hst.aau.dk

📞 +4521397785

Frequently Asked Questions

Who can join the NCT06340438 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Histamine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06340438 currently recruiting?

Yes, NCT06340438 is actively recruiting participants. Contact the research team at slv@hst.aau.dk for enrollment information.

Where is the NCT06340438 trial being conducted?

This trial is being conducted at Aalborg, Denmark.

Who is sponsoring the NCT06340438 clinical trial?

NCT06340438 is sponsored by Aalborg University. The trial plans to enroll 46 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology